• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

未经治疗的视网膜母细胞瘤的自然病史。

Natural History of Untreated Retinoblastoma.

作者信息

Zhao Junyang, Feng Zhaoxun, Gallie Brenda L

机构信息

Department of Ophthalmology, Chongqing Aier Children's Eye Hospital, Chongqing 400020, China.

Department of Ophthalmology, University of Ottawa, Ottawa, ON K1H 8M2, Canada.

出版信息

Cancers (Basel). 2021 Jul 21;13(15):3646. doi: 10.3390/cancers13153646.

DOI:10.3390/cancers13153646
PMID:34359552
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8344972/
Abstract

Treatment abandonment is a leading cause of death in children with retinoblastoma worldwide. We studied children who abandoned treatment upfront at diagnosis to delineate the natural history of untreated retinoblastoma. Studied were children who received no treatment, diagnosed between 2007 and 2017 at 29 Chinese centers. Data were retrospectively collected from medical chart reviews and interviews with each patient's family. During the study period, 44 children received no treatment after diagnosis of retinoblastoma. Clinical or radiologic evidence of orbital extension was available for 25 children, and radiologic evidence of systemic metastasis was available for 12 children. Median times from diagnosis of intraocular tumor to orbital disease was 13.7 months, orbital disease to metastasis was 2.6 months, and metastasis to death was 2.0 months. Children with brain metastasis had shorter survival than those with metastasis to other sites (median 1.0 vs. 3.1 months; = 0.015). Overall, 36% of patients died within 12 months of diagnosis, 77% within 24 months, 95% within 36 months and 100% within 48 months. While multiple factors influence refusal of treatment, insights into the natural history of retinoblastoma derived from real-world evidence can inform clinicians and parents that retinoblastoma is life-threatening and encourage urgent treatment at diagnosis.

摘要

在全球范围内,放弃治疗是视网膜母细胞瘤患儿的主要死因。我们对诊断时即直接放弃治疗的患儿进行了研究,以描绘未经治疗的视网膜母细胞瘤的自然病程。研究对象为2007年至2017年期间在中国29个中心确诊后未接受任何治疗的患儿。数据通过病历回顾以及与每位患儿家属的访谈进行回顾性收集。在研究期间,44例视网膜母细胞瘤患儿确诊后未接受治疗。25例患儿有眼眶扩展的临床或影像学证据,12例患儿有全身转移的影像学证据。从眼内肿瘤诊断到眼眶病变的中位时间为13.7个月,从眼眶病变到转移的中位时间为2.6个月,从转移到死亡的中位时间为2.0个月。发生脑转移的患儿比转移至其他部位的患儿生存时间更短(中位时间1.0个月对3.1个月;P = 0.015)。总体而言,36%的患者在诊断后12个月内死亡,77%在24个月内死亡,95%在36个月内死亡,100%在48个月内死亡。虽然多种因素影响治疗的拒绝,但从真实世界证据中获得的关于视网膜母细胞瘤自然病程的见解可以告知临床医生和家长,视网膜母细胞瘤会危及生命,并鼓励在诊断时进行紧急治疗。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/148b/8344972/1184a343f61e/cancers-13-03646-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/148b/8344972/5ac71d26fef8/cancers-13-03646-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/148b/8344972/53c3e2c8f9e5/cancers-13-03646-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/148b/8344972/1184a343f61e/cancers-13-03646-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/148b/8344972/5ac71d26fef8/cancers-13-03646-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/148b/8344972/53c3e2c8f9e5/cancers-13-03646-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/148b/8344972/1184a343f61e/cancers-13-03646-g003.jpg

相似文献

1
Natural History of Untreated Retinoblastoma.未经治疗的视网膜母细胞瘤的自然病史。
Cancers (Basel). 2021 Jul 21;13(15):3646. doi: 10.3390/cancers13153646.
2
Pre-enucleation chemotherapy for eyes severely affected by retinoblastoma masks risk of tumor extension and increases death from metastasis.眼内期化疗治疗严重受视网膜母细胞瘤影响的眼睛会掩盖肿瘤扩散的风险,并增加因转移而死亡的风险。
J Clin Oncol. 2011 Mar 1;29(7):845-51. doi: 10.1200/JCO.2010.32.5332. Epub 2011 Jan 31.
3
Extra-ocular retinoblastoma: about 12 cases followed at the Mohamed VI university hospital of Marrakech.眼外视网膜母细胞瘤:马拉喀什穆罕默德六世大学医院随访的约12例病例。
Pan Afr Med J. 2016 Nov 2;25:131. doi: 10.11604/pamj.2016.25.131.8599. eCollection 2016.
4
Causes of death and survival analysis for patients with retinoblastoma in Jordan.约旦视网膜母细胞瘤患者的死因及生存分析
Front Med (Lausanne). 2023 Sep 4;10:1244308. doi: 10.3389/fmed.2023.1244308. eCollection 2023.
5
Delayed Enucleation With Neoadjuvant Chemotherapy in Advanced Intraocular Unilateral Retinoblastoma: AHOPCA II, a Prospective, Multi-Institutional Protocol in Central America.晚期单侧眼内进展性视网膜母细胞瘤的新辅助化疗后眼内容剜除术:中美洲前瞻性多中心 AHOPCA II 方案。
J Clin Oncol. 2019 Nov 1;37(31):2875-2882. doi: 10.1200/JCO.18.00141. Epub 2019 Sep 19.
6
Global Retinoblastoma Presentation and Analysis by National Income Level.按国民收入水平对全球视网膜母细胞瘤的呈现与分析
JAMA Oncol. 2020 May 1;6(5):685-695. doi: 10.1001/jamaoncol.2019.6716.
7
Outcome of extraocular retinoblastoma in a resource limited center from low middle income country.来自低收入中等收入国家资源有限中心的眼外视网膜母细胞瘤的治疗结果
Pediatr Hematol Oncol. 2017 Nov;34(8):419-424. doi: 10.1080/08880018.2017.1422060. Epub 2018 Jan 16.
8
Management of massive orbital involvement of intraocular retinoblastoma.眼内视网膜母细胞瘤大量眼眶受累的处理
Ophthalmology. 1998 Feb;105(2):322-6. doi: 10.1016/s0161-6420(98)93367-x.
9
Retinoblastoma in Taiwan: survival rate and prognostic factors.台湾视网膜母细胞瘤:生存率及预后因素
Jpn J Ophthalmol. 2006 May-Jun;50(3):242-9. doi: 10.1007/s10384-005-0320-y.
10
Clinical and epidemiological characteristics of retinoblastoma: correlation with prognosis in a Turkish pediatric oncology center.视网膜母细胞瘤的临床与流行病学特征:土耳其一家儿科肿瘤中心的预后相关性
Pediatr Hematol Oncol. 2007 Apr-May;24(3):221-31. doi: 10.1080/08880010601107623.

引用本文的文献

1
Update on Retinoblastoma Therapies.视网膜母细胞瘤治疗进展
Medicina (Kaunas). 2025 Jul 4;61(7):1219. doi: 10.3390/medicina61071219.
2
Deep learning volumetrics reveal distinct clinical trajectories for pediatric low-grade gliomas under surveillance: A multicenter study.深度学习体积测量揭示了接受监测的儿童低级别胶质瘤的不同临床轨迹:一项多中心研究。
Neurooncol Adv. 2025 Jul 1;7(1):vdaf145. doi: 10.1093/noajnl/vdaf145. eCollection 2025 Jan-Dec.
3
Retinoblastoma in a Young Nigerian Girl: A Case Report From ECWA Eye Hospital, Kano.

本文引用的文献

1
Impact of Systemic Chemotherapy and Delayed Enucleation on Survival of Children with Advanced Intraocular Retinoblastoma.全身化疗和延迟眼摘术对晚期眼内视网膜母细胞瘤患儿生存的影响。
Ophthalmol Retina. 2020 Jun;4(6):630-639. doi: 10.1016/j.oret.2020.02.015. Epub 2020 Mar 4.
2
Delayed Enucleation With Neoadjuvant Chemotherapy in Advanced Intraocular Unilateral Retinoblastoma: AHOPCA II, a Prospective, Multi-Institutional Protocol in Central America.晚期单侧眼内进展性视网膜母细胞瘤的新辅助化疗后眼内容剜除术:中美洲前瞻性多中心 AHOPCA II 方案。
J Clin Oncol. 2019 Nov 1;37(31):2875-2882. doi: 10.1200/JCO.18.00141. Epub 2019 Sep 19.
3
一名年轻尼日利亚女孩的视网膜母细胞瘤:来自卡诺伊夸伊基督教会医院的病例报告
Case Rep Ophthalmol Med. 2025 Jun 8;2025:1733830. doi: 10.1155/crop/1733830. eCollection 2025.
4
Challenges and Outcomes of Retinoblastoma Treatment in Ethiopia A Case of Jimma University Medical Center, Southwest Ethiopia.埃塞俄比亚视网膜母细胞瘤治疗的挑战与结果——以埃塞俄比亚西南部吉马大学医学中心为例
Ethiop J Health Sci. 2025 Mar;35(2):96-100. doi: 10.4314/ejhs.v35i2.5.
5
Incidence, mortality, and global burden of retinoblastoma in 204 countries worldwide from 1990 to 2021: Data and systematic analysis from the Global Burden of Disease Study 2021.1990年至2021年全球204个国家视网膜母细胞瘤的发病率、死亡率及全球疾病负担:全球疾病负担研究2021的数据与系统分析
Neoplasia. 2025 Feb;60:101107. doi: 10.1016/j.neo.2024.101107. Epub 2024 Dec 25.
6
Intraocular Surgery for Retinoblastoma: An Evaluation of Current Evidence.视网膜母细胞瘤的眼内手术:当前证据评估
Ocul Oncol Pathol. 2024 Dec;10(4):234-246. doi: 10.1159/000538626. Epub 2024 Jun 24.
7
Mimicking Retinoblastoma Treatment With Repeated Topotecan or Melphalan Develops Cross-Resistance to Classic Agents But Not to Repurposed Drugs.用反复给予拓扑替康或美法仑模拟视网膜母细胞瘤治疗会产生对经典药物的交叉耐药性,但对重新利用的药物不会产生交叉耐药性。
Invest Ophthalmol Vis Sci. 2024 Dec 2;65(14):14. doi: 10.1167/iovs.65.14.14.
8
A prospective registry study of the epidemiology and management of childhood cancer in the Gambia-The first year experience.冈比亚儿童癌症流行病学与管理的前瞻性登记研究——第一年经验
Health Sci Rep. 2024 Sep 23;7(9):e70084. doi: 10.1002/hsr2.70084. eCollection 2024 Sep.
9
Philippine retinoblastoma initiative multi-eye center study 2010-2020.菲律宾视网膜母细胞瘤倡议多眼中心研究2010 - 2020年
Int J Ophthalmol. 2024 Jan 18;17(1):144-156. doi: 10.18240/ijo.2024.01.20. eCollection 2024.
10
Presentation pattern and survival rate of retinoblastoma following chemotherapy: a prospective study.化疗后视网膜母细胞瘤的表现模式和生存率:一项前瞻性研究。
BMC Pediatr. 2023 Oct 28;23(1):538. doi: 10.1186/s12887-023-04347-w.
Metastases and death rates after primary enucleation of unilateral retinoblastoma in the USA 2007-2017.
2007-2017 年美国单侧视网膜母细胞瘤初次眼球摘除术后的转移率和死亡率。
Br J Ophthalmol. 2019 Sep;103(9):1272-1277. doi: 10.1136/bjophthalmol-2018-312915. Epub 2018 Oct 25.
4
Ten-year experience with ophthalmic artery chemosurgery: Ocular and recurrence-free survival.眼动脉化疗 10 年经验:眼部和无复发生存。
PLoS One. 2018 May 23;13(5):e0197081. doi: 10.1371/journal.pone.0197081. eCollection 2018.
5
Characterization, treatment and prognosis of retinoblastoma with central nervous system metastasis.伴有中枢神经系统转移的视网膜母细胞瘤的特征、治疗及预后
BMC Ophthalmol. 2018 Apr 23;18(1):107. doi: 10.1186/s12886-018-0772-8.
6
Factors associated with abandonment of therapy by children diagnosed with solid tumors in Peru.秘鲁诊断为实体瘤的儿童放弃治疗的相关因素。
Pediatr Blood Cancer. 2018 Jun;65(6):e27007. doi: 10.1002/pbc.27007. Epub 2018 Feb 12.
7
Retrospective investigation of retinoblastoma in Chinese patients.中国患者视网膜母细胞瘤的回顾性调查。
Oncotarget. 2017 May 23;8(65):108492-108497. doi: 10.18632/oncotarget.18174. eCollection 2017 Dec 12.
8
RETINOBLASTOMA IN INDIA: Clinical Presentation and Outcome in 1,457 Patients (2,074 Eyes).印度的视网膜母细胞瘤:1457 例患者(2074 只眼)的临床表现和结局。
Retina. 2019 Feb;39(2):379-391. doi: 10.1097/IAE.0000000000001962.
9
Pars Plana Vitrectomy and Endoresection of Refractory Intraocular Retinoblastoma.玻璃体视网膜切除术及难治性眼内视网膜母细胞瘤的内界膜剥除术
Ophthalmology. 2018 Feb;125(2):320-322. doi: 10.1016/j.ophtha.2017.10.015. Epub 2017 Nov 16.
10
Long-term outcomes of Group D retinoblastoma eyes during the intravitreal melphalan era.玻璃体内注射美法仑时代D组视网膜母细胞瘤眼的长期预后
Pediatr Blood Cancer. 2017 Dec;64(12). doi: 10.1002/pbc.26696. Epub 2017 Jun 24.